Canagliflozin Reduces the Risk of Kidney Failure in Patients with Type 2 Diabetes Mellitus and Nephropathy: the CREDENCE Randomized Trial

This is a preview of subscription content, access via your institution.

Fig. 1

References

  1. 1.

    International Diabetes Federation. IDF diabetes atlas. 8th ed. Brussels: International Diabetes Federation, 2017

    Google Scholar 

  2. 2.

    Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet 2015;385:1975-1982

    Article  Google Scholar 

  3. 3.

    Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644-657

    CAS  Article  Google Scholar 

  4. 4.

    Perkovic V, Jardine M.J., Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380:2295-2306

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Alexandra Halalau MD, MSc.

Ethics declarations

The authors have no conflict of interest to disclose.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Halalau, A., Fuller, W. & Wheeler, S. Canagliflozin Reduces the Risk of Kidney Failure in Patients with Type 2 Diabetes Mellitus and Nephropathy: the CREDENCE Randomized Trial. J GEN INTERN MED (2021). https://doi.org/10.1007/s11606-020-06216-z

Download citation